Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

16.04.21	New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis (GlobeNewswire)
15.04.21	Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA) (GlobeNewswire)
13.04.21	FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications (GlobeNewswire)
12.04.21	Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% (GlobeNewswire)
08.04.21	New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio (GlobeNewswire)
07.04.21	Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types (GlobeNewswire)
31.03.21	Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging (GlobeNewswire)
30.03.21	Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy (GlobeNewswire)
26.03.21	Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer (GlobeNewswire)
25.03.21	Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash (GlobeNewswire)
23.03.21	Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency (GlobeNewswire)
23.03.21	New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 (GlobeNewswire)
22.03.21	Roche provides update on tominersen programme in manifest Huntington’s disease (GlobeNewswire)
22.03.21	Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning (GlobeNewswire)
17.03.21	Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs (GlobeNewswire)
16.03.21	Roche Annual General Meeting 2021 (GlobeNewswire)
16.03.21	Roche Generalversammlung 2021 (GlobeNewswire)
16.03.21	Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations (GlobeNewswire)
16.03.21	New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) (GlobeNewswire)
15.03.21	Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample (GlobeNewswire)
11.03.21	Roche’s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems (GlobeNewswire)
11.03.21	Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia (GlobeNewswire)
08.03.21	Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer (GlobeNewswire)
05.03.21	Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung di (GlobeNewswire)
26.02.21	Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany (GlobeNewswire)
26.02.21	EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 (GlobeNewswire)
26.02.21	Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older (GlobeNewswire)
25.02.21	Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine (GlobeNewswire)
12.02.21	New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially red (GlobeNewswire)
08.02.21	FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weig (GlobeNewswire)
04.02.21	Roche reports solid results in 2020 (GlobeNewswire)
04.02.21	Roche mit solidem Jahresergebnis für 2020 (GlobeNewswire)
01.02.21	Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection (GlobeNewswire)
25.01.21	Roche renews partnership with Sysmex to deliver haematology testing solutions (GlobeNewswire)
25.01.21	Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degenerati (GlobeNewswire)
18.01.21	Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy (GlobeNewswire)
18.01.21	Ordentliche Roche Generalversammlung 2021: Abstimmungen und Wahlen durch die unabhängige Stimmrechtsvertreterin (GlobeNewswire)
12.01.21	Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab (GlobeNewswire)
12.01.21	Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer (GlobeNewswire)
11.01.21	Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer (GlobeNewswire)
11.01.21	Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years (GlobeNewswire)
05.01.21	Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer (GlobeNewswire)
23.12.20	European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer (GlobeNewswire)
21.12.20	Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness (GlobeNewswire)
15.12.20	Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark (GlobeNewswire)
14.12.20	FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis (GlobeNewswire)
11.12.20	Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients (GlobeNewswire)
10.12.20	Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 (GlobeNewswire)
09.12.20	Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials (GlobeNewswire)
08.12.20	Roche presents new data from its bispecific antibody portfolio across a range of blood cancers (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus
22.11.24		Freundlicher Handel: Börsianer lassen SPI schlussendlich steigen
22.11.24		Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone
22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün